Effect of iron chelation on inflammatory joint disease

F J ANDREWS,1 C J MORRIS,1 G KONDRA TOWICZ,2 AND D R BLAKE1

From the 1Rheumatism Research Wing and the 2Department of Pathology, The Medical School, University of Birmingham

SUMMARY Mild iron deficiency induced by treatment with the iron chelator desferrioxamine reduced the incidence and severity of joint inflammation associated with adjuvant disease in rats but did not alter the local primary inflammatory response or the systemic sequelae. Both rats treated with desferrioxamine and control rats showed increased levels of α1 acid glycoprotein, characteristic pathological changes in the liver and inguinal lymph nodes, and the primary inflammatory response at the site of injection. Histology, microfocal radiography, and gross assessment of the joints, however, showed a suppression or reduction in soft tissue swelling and bone erosion in the rats treated with desferrioxamine. This is a novel observation suggesting an apparently selective influence of iron on joint mediated inflammation.

Key words: inflammation, arthritis.

Any sustained inflammatory reaction causes significant changes in iron metabolism with a drop in serum iron and a redistribution of iron to the activated reticuloendothelial system. Muirden and Senator were one of the first to suggest that in rheumatoid arthritis, iron within the synovium (an extension of the reticuloendothelial system) may exacerbate the inflammatory reaction.1 This view has received support from several clinical observations: in early rheumatoid arthritis high levels of synovial iron anticipated a poor prognosis.2 Iron dextran treatment will exacerbate rheumatoid disease, and the effect appears to be mediated by iron (rather than the dextran component), involving the promotion of lipid peroxidation.3 To investigate further the possible role of iron in joint inflammation we have studied the effect of iron chelation using desferrioxamine (DFX) in adjuvant disease in rats. Desferrioxamine has been used successfully in reducing both acute4 and chronic5 inflammation.

Adjuvant disease was selected as an appropriate model to continue our studies as iron deposits are present within the inflamed synovium,6 and the histological features of the adjuvant synovium are a reasonably close approximation to those found in rheumatoid arthritis. Erosive bone damage appears to be a consequence of this inflammation. In addition, adjuvant disease has a ‘systemic’ extra-articular component which also has some features in common with the extra-articular features of rheumatoid disease.7

Materials and methods

Male inbred Wistar rats (200 g) were obtained from Bantin and Kingman (Hull, UK). Adjuvant arthritis was induced on day 0 using the method of Kaibara et al.8 All rats received a single intradermal injection in the base of the tail of 0.1 ml of a 10 mg/ml suspension of Mycobacterium butyricum (Difco, Surrey, UK) in liquid paraffin oil. Animals were killed on days 18, 22, or 34 depending upon the extent of joint inflammation.

IRON LEVELS

Rats were divided into five groups of 12. Group A received daily intraperitoneal injections of 100 mg/kg DFX from day 0. Group B received the same treatment but from day 12 (found from previous experiments to be the usual time of onset of joint inflammation). Group C received daily intraperitoneal injections of 200 mg/kg DFX from day 0 and group D the same treatment from day 12. The control group E received daily intraperitoneal injections of sterile saline, the diluent for the DFX.

In all animals the haemoglobin levels were assessed at the time of death by a cyanomethaemoglobin technique (Sigma, USA). Liver iron stores were
assessed histochemically using Perls' Prussian blue stain based on the method described by Drury and Wallington. The results of the Perls' technique were controlled using known positive sections. Factors which could affect the intensity of the reaction such as staining time and ferrocyanide concentration were strictly standardised. A subjective score of 0-4 was allocated to each section of rat liver corresponding to the level of stainable iron. With a score of 0 there was a total absence of stainable iron and a score of 4 corresponded to >30 Perls' positive cells per high power field chosen at random.

**LOCAL INFLAMMATION**
The development of an inflammatory focus at the site of injection of adjuvant was noted. The extent of reaction was assessed by measuring the diameter of the lesion and by histological assessment of the haematoxylin/eosin (H/E) stained sections of the tail. As we have noted that the primary inflammatory lesion is associated with periostitis of underlying vertebrae at the base of the tail this was assessed by microfocal radiography (see below).

**JOINT INFLAMMATION**
Joint inflammation was assessed by an established method based on the foot scoring system first described by Currey and Ziff. A subjective score of 0-4 was allocated to each hind foot depending upon the extent of the inflammation, with a maximum score of 8 per rat. Zero represented no inflammation, 1 represented slight redness and swelling of the foot, 2 represented swelling of the foot such that the tendons were no longer visible, 3 represented swelling extending to the ankle joint, and a score of 4 represented gross inflammation and deformity of the ankle joint.

At the time of death both back legs were removed and fixed in buffered formal saline. Joints were randomly selected for histology and radiography. Where rat ankle joints were selected for histology, radiography was carried out on the opposite ankle joint from the same rat.

**Histology**
Ankle joints were decalcified in 10% formic acid and processed using a double embedding technique. Paraffin wax sections (5 μm) were cut and stained with H/E. Sections were assessed by two observers.

**Microfocal radiography**
The x ray system used in this work comprised a demountable x ray unit, an X-Y positioning frame, and Marconi image intensifier and monitor. The special 25 μm microfocal x ray set had an effective resolution of >20 lp/mm. Radiographs were obtained at a magnification of ×10 for the feet and ×4 for the tails using standard x ray cassettes positioned in front of the image intensifier. Exposures were 60 kV and 1 mAS (0.5 mA).

Radiographs were assessed by two observers.

**SYSTEMIC DISEASE**

**Lymph nodes**
Several studies have shown that lymph nodes have a role in the draining of the site of inoculation in the early phase of development of adjuvant disease. The inguinal lymph nodes were removed from all the rats at the time of death and were processed by a standard histological procedure. The hyperplastic response of the lymph nodes to adjuvant was assessed semiquantitatively by measuring the maximum diameter of the nodes and determining the number of follicles with germinal centre formation. The presence or absence of granuloma formation, paracortical hyperplasia, sinus histiocytosis, and dilatation were recorded. Sections of lymph node were stained for Perls' iron as described above.

**Liver**
Samples of liver were removed from all the rats and processed by a standard histological procedure. The presence of foci of inflammatory cells or granulomas, or both, in the liver are a feature of adjuvant disease. H/E sections of liver from all the rats were assessed and the presence/absence of these features recorded in 10 high power fields of the section selected at random.

**α1 Acid glycoprotein**
α1 Acid glycoprotein levels were assessed in the plasma from all the rats at the time of death by an immunodiffusion method. Antiserum, pooled acute and pooled normal rat plasma were obtained from Dr M Billingham (Eli Lilley, Surrey, UK). Inter- and intraplate variation were calculated using pooled acute and normal rat plasma with known levels of α1 acid glycoprotein. Normal levels of α1 acid glycoprotein were obtained from the plasma of control rats of the same age, strain, and sex as the test rats.

**Statistics**
Analysis of parametric data was carried out using Student's t test and the data are expressed as the mean (SD). Non-parametric data were analysed using a Mann-Whitney U test.

**Results**

**Iron levels**
Iron chelation with DFX did not significantly affect
haemoglobin levels (100 mg/kg DFX: 167 (SD 16 g/l, 200 mg/kg DFX: 162 (17) g/l, saline: 159 (14) g/l; Student’s t test). Control rats with no adjuvant disease but of the same age, strain, and sex had haemoglobin levels of 169 (2) g/l. DFX treatment reduced iron stores. Sixty two per cent of rats treated with DFX (irrespective of dose) had no stainable iron present in the liver, the remaining 38% had very low levels (grade 1). All the control rats had evidence of stainable iron in the liver: 29% had grade 1 levels, 42% grade 2, and 29% grade 3.

**Local Inflammation**

All the rats developed a primary inflammatory focus at the site of injection in the base of the tail. There was no significant difference in the diameter of the lesion (DFX 100 mg/kg: 9·0 (SD 5·9) mm, DFX 200 mg/kg: 14·2 (8·7) mm, saline: 10·0 (6·2) mm; Student’s t test).

Histological investigation of H/E stained sections showed the lesion consisted of ulceration of the epidermis with underlying granulation tissue formation. The granulation tissue contained a mixed inflammatory cell infiltrate consisting mainly of lymphocytes, histiocytic cells with some polymorphs, and occasional Langhans’ type giant cells.

Microfocal radiographs of the tail showed an intense periostitis, florid new bone formation, and evidence of bone destruction in the vertebrae underlying the injection site. Both DFX treated and control rats had the same type and extent of reaction at the injection site as assessed histologically and by microfocal radiography.

**Joint Inflammation**

Initial signs of arthritis were noted from day 12. Between days 12 and 13 there was no significant difference in joint score between the DFX and control rats. By day 14, however, 100% of the control rats had joint scores of 2 or more compared with only 8% of rats receiving 100 mg/kg DFX and 25% of rats receiving 200 mg/kg DFX. Analysis of the foot score data showed a significant reduction in the degree of inflammation from day 14 onwards in the DFX treated animals (Fig. 1). There was no significant difference in joint inflammation between the two doses of DFX nor was there any difference associated with the time of treatment. All control rats were killed by day 22 because of the severity of joint inflammation, but 79% of rats receiving DFX treatment had mild or no joint inflammation by day 34.

**Histology**

H/E stained sections of a random selection of control rat ankle joints showed a florid erosive arthritis. The synovium showed proliferation with a dense infiltration of polymorphs and some histiocytes but an almost complete absence of lymphocytes and plasma cells. Considerable soft tissue oedema was noted. Inflammatory granulation tissue extended into and eroded the subchondral bone, particularly of the tibia, and there was considerable osteoblast and osteoclast activity with bone resorption and reactive bone formation. The articular cartilage was remarkably well preserved. No evidence of vasculitis was seen.

H/E sections of DFX treated rat ankle joints chosen at random showed little or no inflammatory changes in most of the tissue studied. On some sections a mild synovitis with soft tissue swelling was observed, but there was no evidence of bone erosion on these sections. The overall histological appearances support our gross ‘clinical’ assessments of inflammation, indicating a reduction in both the incidence and severity of the joint inflammation associated with DFX treatment.

**Microfocal radiography**

Radiography of the other hind foot from each rat reflected histological findings and gross clinical assessment. Microfocal radiography of control joints showed marked destructive lesions of the peripheral metaphyses, consisting of periostitis, osteoporosis (especially of the tibia head) with new bone formation, and considerable soft tissue swelling.

The ankle joints of DFX treated animals showed no evidence of bone changes.

**Systemic Diseases**

**Lymph nodes**

Inguinal lymph nodes from both DFX and saline treated rats showed a similar response to the adjuvant. There was no significant difference in the diameter of nodes (DFX 100 mg/kg: 3·9 (SD 2·2) mm, DFX 200 mg/kg: 5·4 (2·3) mm, saline: 5·2 (2·0) mm; Student’s t test), presence or absence of paracortical hyperplasia, sinus histiocytosis, and dilatation, nor in the proportion of nodes in each group showing secondary follicle formation (69% of rats treated with DFX showed secondary follicle formation compared with 85% of rats treated with saline (Mann-Whitney)). Surprisingly, there was no significant difference in the amount of stainable iron in the lymph nodes of rats receiving either dose of DFX and the saline treated rats, the mean iron score in each group being 2. DFX treated rats, however, had significantly less granulomas in the lymph nodes, 31% of animals showing granulomas compared with 71% of saline treated rats (Mann-Whitney, p<0·05).
Fig. 1 Change in foot score with time. Comparison of DFX and saline treated rats. *p<0.05; **p<0.01 (Mann-Whitney). n=12.
Liver
Similar pathological changes were noted in both DFX and saline treated animals. There was no significant difference in the number of rats showing granulomas in the liver: 23% of DFX treated rats compared with 29% of saline treated rats. Sixty two per cent of DFX treated rats showed foci of inflammatory cells in the liver compared with 71% of saline treated rats; again these results showed no significant differences (Mann-Whitney). Areas of necrosis in the liver were noted in one DFX treated and one saline treated rat.

$\alpha_i$ Acid glycoprotein
$\alpha_i$ Acid glycoprotein levels were found to be raised in DFX treated and saline treated rats as a result of adjuvant disease (DFX 200 mg/kg: 7-01 (SD 4-20 g/l, DFX 100 mg/kg: 6-55 (4-90) g/l, saline: 9-89 (4-84) g/l). Control rats of the same age, strain, and sex with no adjuvant disease had levels of 0-50 (0-11) g/l.

There was no significance in the levels of $\alpha_i$ acid glycoprotein related to joint inflammation or iron deficiency.

Discussion
In 1956 Pearson first described a generalised or focal arthritis, synovitis, and tendinitis in rats injected with Freund's complete adjuvant.15 Subsequent reports have shown the systemic nature of the disease affecting a range of tissues including joints, eyes, skin, urogenital and gastrointestinal systems.16-17

Our results show that the iron chelator DFX when given in a dose capable of reducing reticuloendothelial (hepatic) iron stores will selectively suppress joint inflammation without modifying either the primary inflammatory reaction at the injection site or the systemic sequelae.

Adjuvant disease has been shown to follow a time course characterised by alterations in clinical, pathological, and biochemical parameters. Initially there is an acute local inflammatory response at the site of the injection.18 Biochemically this phase is distinguished by an increase in plasma $\alpha_i$ acid glycoprotein, reflecting a systemic response to an acute local inflammation.19 Iron chelation did not appear to alter this initial response: the size of the tail lesion, the histology, and microfocal radiography of the underlying vertebrae showed similar changes in both DFX treated and control rats; plasma $\alpha_i$ acid glycoprotein levels were raised in both groups of animals.

The next phase is characterised by the development of the arthritis which occurs from around day 12 and comprises extensive inflammation of the hind paws followed by the fore paws and spine.20 Iron chelation significantly suppressed this aspect of the disease. Rats treated with DFX had a reduced incidence and severity of joint inflammation as assessed by subjective scoring, histology, and microfocal radiography.

Joint inflammation is accompanied by the development of systemic pathology. Granulomas have been observed in the lungs, lymph nodes, spleen, liver, and heart of rats with adjuvant disease,21 and hyperplasia of the lymph nodes draining the inoculation site has been reported.13 It is thought that the earliest lesions are quite similar histologically in all the affected tissues, including the joints,22-23 and that rats failing to develop arthritis also fail to develop other lesions.16 This is clearly incorrect. Iron chelation did not appear to affect the development of granulomas in the liver or the presence of paracortical hyperplasia, dilatation, and histiocytosis of the sinuses or secondary follicle formation in the draining lymph nodes. These results would suggest that different mechanisms influence joint inflammation as opposed to the systemic lesions.

Like rheumatoid disease the aetiology of adjuvant disease is not firmly established but is thought to involve immune mechanisms either in the development of the disease24 or as an exacerbatory influence.25 Iron deficiency may impair both humoral26 and cell mediated immunity27 in rats, and it is therefore possible that iron deficient immune suppression is responsible for the reduction in joint inflammation observed in the DFX treated group. This does not easily explain, however, the presence of systemic disease and especially the changes observed in the lymph nodes of the DFX treated rats.

Free metal ions including iron will catalyse the formation of the hydroxyl radical from the superoxide radical and hydrogen peroxide.28 Both reactive oxygen metabolites are produced from stimulated neutrophils, monocytes, and macrophages.29 The hydroxyl radical is highly reactive and will damage a variety of biomolecules, including polyunsaturated fatty acids, by the process of lipid peroxidation. Not only is there a tendency for the inflamed joint to accumulate iron as a consequence of microbleeding30 but it also provides a suitable environment for iron mediated damage. In rheumatoid arthritis, low synovial fluid pH is thought to allow the release of iron from transferrin, providing a form of iron capable of catalysing the formation of the hydroxyl radical.31 In adjuvant disease we found large numbers of neutrophils and macrophages in the inflamed synovial tissue. This together with the observation that high levels of lipid peroxidation products occur in the synovial fluid of rats with adjuvant disease32 suggests a role

Effect of iron chelation on inflammatory joint disease 331
for free radical mediated damage in this model. Iron chelation may specifically protect the joint in adjuvant disease by reducing levels of iron available for the promotion of hydroxyl radical formation and subsequent tissue damage. High levels of prostaglandin E\(_2\) (PGE\(_2\)) have been reported in inflamed tissues\(^{33}\) and perfusates\(^{34}\) of adjuvant arthritic ankle joints, and the levels measured reflected the severity of swelling. Both periosteal proliferation and bone resorption may be induced by PGE\(_2\),\(^{35}\) and in vitro studies have shown that iron nitritocacetate will augment the release of PGE\(_2\) from synovial cells in culture.\(^{36}\) Iron chelation may therefore reduce PGE\(_2\) production, inhibiting both the periosteal reaction of adjuvant disease and the erosive consequences of synovial inflammation.

In conclusion, iron chelation appears to have a selective effect in reducing joint inflammation in adjuvant disease. We believe this to be a novel finding, which, taken in conjunction with the clinical observation that the iron dextran selectively exacerbates joint inflammation in rheumatoid disease,\(^3\) suggests a fundamental role for iron in inflammatory joint disease.

This work was supported by grants from West Midlands Regional Health Authority (DRB), British Technology Group (DRB), and the Arthritis and Rheumatism Council for research (CJM, DRB). We are grateful for the assistance of Mr Mike Haddaway and Dr Iain Watt with the microfocal radiography, Mr Mike Robinson and Dr MikeBillingham with the α\(_1\) acid glycoprotein assay, and Miss J Dowson for secretarial assistance.

References

32. Yoshikawa T, Tanaka H, Kanao M. Lipid peroxidation in rat...


Effect of iron chelation on inflammatory joint disease.

F J Andrews, C J Morris, G Kondratowicz and D R Blake

Ann Rheum Dis 1987 46: 327-333
doi: 10.1136/ard.46.4.327

Updated information and services can be found at:
http://ard.bmj.com/content/46/4/327

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/